SCHEMBL5746076

SCHEMBL5746076

Cc1ccc(Cl)cc1N1CCN(S(=O)(=O)c2cccc(CC(=O)O)c2)CC1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.69
TSHR P16473 1/20 0.69
PTPN11 Q06124 1/20 0.58
USP2 O75604 4/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
POLB P06746 4/20 0.55
KDM4E B2RXH2 1/20 0.55
MAPT P10636 3/20 0.54
TP53 P04637 2/20 0.54
NPSR1 Q6W5P4 3/20 0.54
NAMPT P43490 1/20 0.54
HTT P42858 1/20 0.52
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 1/20 0.51
MCOLN3 Q8TDD5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772886 0.90 LMNA (0.69) LMNATSHRUSP2L3MBTL1POLB
SCHEMBL5745462 0.85 MAPT (0.59) LMNATSHRPTPN11USP2CYP2C9
SCHEMBL5749033 0.85 HDAC3 (0.56) LMNATSHRPTPN11USP2KDM4E
SCHEMBL5748086 0.84 MAPT (0.58) LMNAUSP2L3MBTL1POLBMAPT
SCHEMBL5772658 0.84 PTPN11 (0.62) LMNAPTPN11KDM4EHTTMEN1
SCHEMBL5776880 0.84 LMNA (0.59) LMNATSHRPTPN11MAPTALDH1A1
SCHEMBL5749068 0.82 MAPT (0.55) LMNATSHRPTPN11USP2L3MBTL1
SCHEMBL13805030 0.79 ALDH1A1 (0.63) LMNAPOLBKDM4EMEN1ALDH1A1
SCHEMBL6357532 0.79 HTT (0.58) LMNAPTPN11POLBHTTMEN1
SCHEMBL5749330 0.78 THRB (0.58) LMNATSHRPTPN11USP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD LMNA 3289/4885TSHR 140/4885PTPN11 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.